Biopharma Catalyst (FDA Approvals & Data Read outs)

Think animal studies will have any impact?
And given we’re almost halfway through feb now, I’m thinking those results won’t appear until March

My understanding is they did already a human pilot, which was successful, so they go back now to animal study with a broader and more controlled setting before they start human trials again. So maybe not too much of an impact until they start the human trial $KALV positive phase 3 data, up 70% since call out, let’s see how much more fuel it is. 20% up market. Another bio win in the bags $ROIV

  • Brepocitinib topline data from the Phase 2 trial in patients with non-infectious uveitis (NIU) is expected this quarter
  • Roivant reported its consolidated cash, cash equivalents and restricted cash of $6.7B at December 31, 2023, supporting cash runway into profitability

CAN-3110 Receives FDA Fast Track Designation for Treatment CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma $CADL, up in Pre-market. Up 40% from call out. Could be a good time to take profit $COGT up 50% pre market, will take profit today

1 Like

Inspira™ Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System

$IINN, up 20% pre market.

Taking more profit, only a small position left

<@281588131554131968> sell!

I’m out lol

1.50/1.55 big resistance then 1.75

I sold so it could run to 2 for you all

Last time IINN ran they diluted for like 1.28 a share same day it ran so could be similar today and it dropped to under $1 a few days later

CYBN Cash totaled C$39.0 million as of December 31, 2023 .

– With the previously announced public offerings of units of the Company
(the “Units”) and a combination of the Company’s current cash position,
current at-the-market equity program and assuming the exercise in full of
the warrants issued as part of the Units, the Company has access to over
C$121 million .

– Net loss was C$30.3 million for the quarter ended December 31, 2023 ,
compared to a net loss of C$10.7 million in the same period last year.

– Cash-based operating expenses totaled C$17.1 million for the quarter
ended December 31, 2023 , compared to C$11.1 million , in the prior year

– Cash flows used in operating activities were C$19.0 million for the
quarter ended December 31, 2023 , compared to C$10.8 million in the same
period last year.

– Cash flows received from financing activities were C$42.4 million for
the quarter ended December 31, 2023 , compared to C$3.5 million in the
same period last year, related to the net proceeds on the issuance of
Common Shares through the Company’s August 3, 2023 and November 14, 2023
financing and its at-the-market equity program. <@889849212915843093>

Looks like IINN bottom so far 1.13 ish for today after sell off. I want closer to 1 so waiting if going to enter again

$CYBN getting a bit of a sell off today

$VCNX Now you want it to stay away from this green box and never go back there again or bad news… That big fat 4 hour green candle to end the day today says a lot… Very good chance you see .87 taken out before eow… Then things really start to get interesting…image

No not at all, cautiously saying the opposite actually. The fact that we dipped into that green box yesterday and then aggressively blew out of it is exactly what you want to see happen before the next leg up. That big fat green candle from yesterday afternoon is what you want to see of you are bullish. More specifically the wick went below the green bow and you have part of the full green bar formed within the green box (textbook price action, was very happy to see this play out)

VCNX 1 for 14 reverse split